Bajaj Healthcare Ltd vs Parmax Pharma Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 17, 2026

Key Highlights

The Latest Trading Price of Bajaj Healthcare Ltd is ₹ 284.95 as of 15 May 15:30 . The P/E Ratio of Bajaj Healthcare Ltd changed from 7.8 on March 2021 to 53.7 on March 2025 . This represents a CAGR of 47.09% over 5 yearsThe P/E Ratio of Parmax Pharma Ltd changed from 21 on March 2021 to 0 on March 2025 . This represents a CAGR of -100.00% over 5 years The Market Cap of Bajaj Healthcare Ltd changed from ₹ 650.77 crore on March 2021 to ₹ 2121 crore on March 2025 . This represents a CAGR of 26.66% over 5 yearsThe Market Cap of Parmax Pharma Ltd changed from ₹ 13.28 crore on March 2021 to ₹ 15.8 crore on March 2025 . This represents a CAGR of 3.54% over 5 years The revenue of Bajaj Healthcare Ltd for the Mar '26 is ₹ 156.01 crore as compare to the Dec '25 revenue of ₹ 162.87 crore. This represent the decline of -4.21% The revenue of Parmax Pharma Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 4.33 crore. This represent the decline of -100% The ebitda of Bajaj Healthcare Ltd for the Mar '26 is ₹ -11.05 crore as compare to the Dec '25 ebitda of ₹ 31.9 crore. This represent the decline of -134% The ebitda of Parmax Pharma Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ -0.19 crore. This represent the decline of -100% The net profit of Bajaj Healthcare Ltd changed from ₹ 7.13 crore to ₹ -22.85 crore over 8 quarters. This represents a CAGR of NaN% The net profit of Parmax Pharma Ltd changed from ₹ 0.01 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The Dividend Payout of Bajaj Healthcare Ltd changed from 4.57 % on March 2021 to 7.99 % on March 2025 . This represents a CAGR of 11.82% over 5 yearsThe Dividend Payout of Parmax Pharma Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Bajaj Healthcare Ltd

Incorporated in 1993, Maharashtra-based Bajaj Healthcare Limited is one of India's large scale and vertically integrated pharmaceutical manufacturer for quality-conscious customers.
The Company is engaged in the manufacturing and exporting of Active Pharmaceutical Ingredient (APIs), Intermediates, Finished Dosage Forms & Nutraceuticals. Company commenced its operations in 1993 with a single unit at Tarapur.
It became a public company in 2005 and listed its shares in the Indian stock exchanges in 2016. With Headquartered in Thane, Company has established 3 API plants in Gujarat and Maharashtra.
It has 4 units for APIs/ intermediates and one unit for formulation, which are designed to meet the requirements of both advanced as well as emerging market opportunities.
In 2008, the Company acquired Formulations plant at Manjusar, Vadodara and have converted it into WHO-GMP compliant facility.

About Parmax Pharma Ltd

Incorporated in November, 1994, Parmax Pharma Limited (PPL) was promoted by Jayantilal S Dhol, Purushottam J Bhalodi and Prabhudas D Hansalpara.
The Active Pharmaceutical Ingredients (API) and Contract Manufacturing Operations ( CMO) business are the key pillar of Parmax's pharmaceutical operations.
The Company has manufacturing facilities approved by Indian regulatory bodies such as CDSCO, State FDA, and operates under GMP-compliant systems. The Promoters were earlier into manufacturing of bulk drugs like Ampicilin, Amoxycillin, Cephalexin, Nalidixic Acid etc.
The Company then discontinued their business activities for few years due to various reasons.
Starting from their journey as a bulk drug manufacturer and speciality chemicals in 1994; the Company had set up a plant to manufacture and market bulk drugs like amoxycillin tri-hydrate, ampicillin tri-hydrate, cephalexin mono hydrate and nalidixic acid, at Hadamtala, Gujarat, with an installed capacity of 96 TPA.

FAQs for the comparison of Bajaj Healthcare Ltd and Parmax Pharma Ltd

Which company has a larger market capitalization, Bajaj Healthcare Ltd or Parmax Pharma Ltd?

Market cap of Bajaj Healthcare Ltd is 959 Cr while Market cap of Parmax Pharma Ltd is 11 Cr

What are the key factors driving the stock performance of Bajaj Healthcare Ltd and Parmax Pharma Ltd?

The stock performance of Bajaj Healthcare Ltd and Parmax Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Bajaj Healthcare Ltd and Parmax Pharma Ltd?

As of May 17, 2026, the Bajaj Healthcare Ltd stock price is INR ₹284.95. On the other hand, Parmax Pharma Ltd stock price is INR ₹31.17.

How do dividend payouts of Bajaj Healthcare Ltd and Parmax Pharma Ltd compare?

To compare the dividend payouts of Bajaj Healthcare Ltd and Parmax Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.